Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T41963
(Former ID: TTDR00939)
|
|||||
| Target Name |
Toll-like receptor (TLR)
|
|||||
| Synonyms |
Toll-like receptor
Click to Show/Hide
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 7 Target-related Diseases | + | ||||
| 1 | Lung cancer [ICD-11: 2C25] | |||||
| 2 | Rheumatoid arthritis [ICD-11: FA20] | |||||
| 3 | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||||
| 4 | Diffuse large B-cell lymphoma [ICD-11: 2A81] | |||||
| 5 | Mature B-cell lymphoma [ICD-11: 2A85] | |||||
| 6 | Autoimmune disease [ICD-11: 4A40-4A45] | |||||
| 7 | Prostate cancer [ICD-11: 2C82] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 4 Clinical Trial Drugs | + | ||||
| 1 | BDB001 | Drug Info | Phase 2 | Solid tumour/cancer | [2] | |
| 2 | DPV-001 | Drug Info | Phase 2 | Non-small-cell lung cancer | [3] | |
| 3 | IMO-8400 | Drug Info | Phase 2 | Rheumatoid arthritis | [4] | |
| 4 | IMO-9200 | Drug Info | Phase 1 | Autoimmune disease | [4] | |
| Patented Agent(s) | [+] 5 Patented Agents | + | ||||
| 1 | PMID30280939-Compound-US20170128558 | Drug Info | Patented | Malaria | [5] | |
| 2 | PMID30280939-Compound-US20179642901 | Drug Info | Patented | Malaria | [5] | |
| 3 | PMID30280939-Compound-WO2008009652 | Drug Info | Patented | Malaria | [5] | |
| 4 | PMID30280939-Compound-WO2013148426 | Drug Info | Patented | Malaria | [5] | |
| 5 | PMID30280939-Compound-WO2015091734 | Drug Info | Patented | Malaria | [5] | |
| Discontinued Drug(s) | [+] 1 Discontinued Drugs | + | ||||
| 1 | ONO-4007 | Drug Info | Discontinued in Phase 2 | Immune System disease | [6] | |
| Mode of Action | [+] 4 Modes of Action | + | ||||
| Agonist | [+] 12 Agonist drugs | + | ||||
| 1 | BDB001 | Drug Info | [7] | |||
| 2 | PMID30280939-Compound-US20170128558 | Drug Info | [5] | |||
| 3 | PMID30280939-Compound-US20179642901 | Drug Info | [5] | |||
| 4 | PMID30280939-Compound-WO200606195 | Drug Info | [5] | |||
| 5 | PMID30280939-Compound-WO2008009652 | Drug Info | [5] | |||
| 6 | PMID30280939-Compound-WO2009082440 | Drug Info | [5] | |||
| 7 | PMID30280939-Compound-WO2013119856 | Drug Info | [5] | |||
| 8 | PMID30280939-Compound-WO2013148426 | Drug Info | [5] | |||
| 9 | PMID30280939-Compound-WO2013148427 | Drug Info | [5] | |||
| 10 | PMID30280939-Compound-WO2015035128 | Drug Info | [5] | |||
| 11 | PMID30280939-Compound-WO2015091734 | Drug Info | [5] | |||
| 12 | PMID30280939-Compound-WO2015150568 | Drug Info | [5] | |||
| Modulator | [+] 2 Modulator drugs | + | ||||
| 1 | DPV-001 | Drug Info | [1] | |||
| 2 | ONO-4007 | Drug Info | [9] | |||
| Antagonist | [+] 2 Antagonist drugs | + | ||||
| 1 | IMO-8400 | Drug Info | [4], [8] | |||
| 2 | IMO-9200 | Drug Info | [4] | |||
| Immune response agent | [+] 1 Immune response agent drugs | + | ||||
| 1 | PMID30280939-Compound-WO2005070959 | Drug Info | [5] | |||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | UbiVac's DRibble, autophagosome-enriched vaccines: Applications for cancer and infectious disease. UbiVac. 2013. | |||||
| REF 2 | ClinicalTrials.gov (NCT04819373) BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors. U.S. National Institutes of Health. | |||||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038474) | |||||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 5 | Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847. | |||||
| REF 6 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003036) | |||||
| REF 7 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 8 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 9 | Toll-like receptors TLR2 and TLR4 initiate the innate immune response of the renal tubular epithelium to bacterial products. Clin Exp Immunol. 2006 August; 145(2): 346-356. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.